2020 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2020-02-01±³À°ÀÏÀÚ : 2020-02-01
±³À°Àå¼Ò : ¼¿ï´ëÇб³ Ä¡°úº´¿ø 8Ãþ ´ë°°
±³À°ÁÖÁ¦ :
2020 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ¼¼Æ÷Ä¡·á¿¬±¸È¸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
bmt@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 10:00~10:40 Cancer Immunotherapy; past, present and future ¹è¿ë¼ö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 10:40~11:10 Biomedical applications of stimuli responsive nanoparticles ¹ÚÀαÔ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 11:10~11:40 Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy À̽¿ì(Æ÷Ç×°ø´ë)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 11:40~12:10 NK cells in cancer immunosurveillance and prognosis ±èÇå½Ä(¿ï»êÀÇ´ë)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 13:20~14:00 Real world experience of CAR T-cell therapy Peihua Lu(Hebei Yanda Lu Daopei Hospital, China)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 14:00~14:30 Novel immunotherapeutic approach with antibody drugs Á¤ÀçÈ£(ABL Bio)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 14:30~15:00 Current status of bispecific T-cell engager for B cell ALL À±ÀçÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 15:10~15:50 Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes Jooeun Bae(Harvard Medical School, USA)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 15:50~16:20 Adoptive T cell immunotherapy – experiences in preclinical and clinical studies ÃÖ¹ü±Ô(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 02-01 8Ãþ ´ë°´ç 16:20~16:50 Overcoming refractoriness to immune checkpoint inhibition in multiple myeloma: an ex vivo evidence of combination approach ÃÖÀ±¼®(Ãæ³²ÀÇ´ë)